Fennec Pharmaceuticals Inc (FENC) FinancialsFENCFinancialFennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. (FENC) generates its revenue primarily from PEDMARK product sales, which accounts for 100.0% of total sales, equivalent to $7.26M. Understanding this concentration is critical for investors evaluating how FENC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Fennec Pharmaceuticals Inc. maintains a gross margin of 95.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.72%, while the net margin is 11.04%. These profitability ratios, combined with a Return on Equity (ROE) of -18.58%, provide a clear picture of how effectively FENC converts its operational activities into shareholder value.

In the context of the broader market, FENC competes directly with industry leaders such as BNTC and PRLD. With a market capitalization of $430.27M, it holds a significant position in the sector. When comparing efficiency, FENC's gross margin of 95.97% stands against BNTC's N/A and PRLD's 100.00%. Such benchmarking helps identify whether Fennec Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Fennec Pharmaceuticals has demonstrated strong revenue growth, with Q1 2026 revenues of $15.11 million, a 72.7% increase year-over-year. The gross margin remains robust at 96.23% for Q1 2026, indicating effective cost management. Despite previous losses, the company reported a net income of $2 million in Q2 2026, marking a significant turnaround.